Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid titration of toludesvenlafaxine XR in major depressive disorder
ChiCTR2600116068Phase 4Not yet recruiting
- Sponsor
- Shanghai Mental Health Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Shanghai Mental Health Center. Primary endpoint: HAMD-17 score change from baseline at week 6. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600116068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116068.